BR0112624A - Virús modificado, proteìna viral modificada, célula permissiva para um vìrus modificado, métodos para produzir um vìrus modificado em cultura de células, para regular a replicação de um vìrus modificado, para determinar a adequalibilidade de um polipeptìdeo não nativo para uso na preparação de um vetor viral e para ensair a solublidade de um polipeptìdeo não nativo ou de uma proteìna viral modificada, uso do vìrus modificado, e, composição farmacêutica - Google Patents

Virús modificado, proteìna viral modificada, célula permissiva para um vìrus modificado, métodos para produzir um vìrus modificado em cultura de células, para regular a replicação de um vìrus modificado, para determinar a adequalibilidade de um polipeptìdeo não nativo para uso na preparação de um vetor viral e para ensair a solublidade de um polipeptìdeo não nativo ou de uma proteìna viral modificada, uso do vìrus modificado, e, composição farmacêutica

Info

Publication number
BR0112624A
BR0112624A BR0112624-5A BR0112624A BR0112624A BR 0112624 A BR0112624 A BR 0112624A BR 0112624 A BR0112624 A BR 0112624A BR 0112624 A BR0112624 A BR 0112624A
Authority
BR
Brazil
Prior art keywords
modified
virus
viral protein
native polypeptide
cell
Prior art date
Application number
BR0112624-5A
Other languages
English (en)
Original Assignee
Got A Gene Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Got A Gene Ab filed Critical Got A Gene Ab
Publication of BR0112624A publication Critical patent/BR0112624A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C12N2810/405—Vectors comprising RGD peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/55—Vectors comprising as targeting moiety peptide derived from defined protein from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/851—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from growth factors; from growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"VìRUS MODIFICADO, PROTEìNA VIRAL MODIFICADA, CéLULA PERMISSIVA PARA UM VìRUS MODIFICADO, MéTODOS PARA PRODUZIR UM VìRUS MODIFICADO EM CULTURA DE CéLULAS, PARA REGULAR A REPLICAçãO DE UM VìRUS MODIFICADO, PARA DETERMINAR A ADEQUABILIDADE DE UM POLIPEPTìDEO NãO NATIVO PARA USO NA PREPARAçãO DE UM VETOR VIRAL E PARA ENSAIAR A SOLUBILIDADE DE UM POLIPEPTìDEO NãO NATIVO OU DE UMA PROTEìNA VIRAL MODIFICADA, USO DO VìRUS MODIFICADO, E, COMPOSIçãO FARMACêUTICA". A presente invenção descreve um vírus modificado que compreende um ou mais polipeptídeos não nativos, que contêm uma ou mais porções da estrutura básica, cada uma contendo uma ou mais porções de ligação, o polipeptídeo sendo capaz de ser expresso no citoplasma e núcleo de uma célula hospedeira de mamífero em uma conformação que seja mantida na ausência de um ligando para referidas porções de ligação, dita conformação permitindo que ditas porções de ligação subseq³entemente se liguem com referido ligando, sendo o polipeptídeo capaz de transporte através da membrana nuclear, em que referido vírus tem um tropismo alterado conferido pelas referidas porções de ligação, e o uso de tais vírus na terapia, particularmente no tratamento de tumores ou outras células cancerosas.
BR0112624-5A 2000-07-19 2001-07-19 Virús modificado, proteìna viral modificada, célula permissiva para um vìrus modificado, métodos para produzir um vìrus modificado em cultura de células, para regular a replicação de um vìrus modificado, para determinar a adequalibilidade de um polipeptìdeo não nativo para uso na preparação de um vetor viral e para ensair a solublidade de um polipeptìdeo não nativo ou de uma proteìna viral modificada, uso do vìrus modificado, e, composição farmacêutica BR0112624A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0017720.4A GB0017720D0 (en) 2000-07-19 2000-07-19 Modified virus
PCT/GB2001/003252 WO2002008263A2 (en) 2000-07-19 2001-07-19 Modified virus having an altered tropism

Publications (1)

Publication Number Publication Date
BR0112624A true BR0112624A (pt) 2003-07-01

Family

ID=9895953

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0112624-5A BR0112624A (pt) 2000-07-19 2001-07-19 Virús modificado, proteìna viral modificada, célula permissiva para um vìrus modificado, métodos para produzir um vìrus modificado em cultura de células, para regular a replicação de um vìrus modificado, para determinar a adequalibilidade de um polipeptìdeo não nativo para uso na preparação de um vetor viral e para ensair a solublidade de um polipeptìdeo não nativo ou de uma proteìna viral modificada, uso do vìrus modificado, e, composição farmacêutica

Country Status (15)

Country Link
US (1) US7456008B2 (pt)
EP (1) EP1301613A2 (pt)
JP (1) JP2004504062A (pt)
CN (1) CN1443243A (pt)
AU (2) AU2001270879B2 (pt)
BR (1) BR0112624A (pt)
CA (1) CA2413851A1 (pt)
CZ (1) CZ2003152A3 (pt)
GB (1) GB0017720D0 (pt)
IL (1) IL153879A0 (pt)
MX (1) MXPA03000449A (pt)
NO (1) NO20030239L (pt)
NZ (1) NZ524251A (pt)
PL (1) PL360350A1 (pt)
WO (1) WO2002008263A2 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077081A1 (en) * 2001-02-07 2004-04-22 Egbert Oosterwijk Hybridoma cell line g250 and its use for producing monoclonal antibodies
EP1385959A2 (en) * 2001-02-07 2004-02-04 Wilex AG Method of producing recombinant antibodies against tumours
ATE537842T1 (de) 2002-07-01 2012-01-15 Wilex Ag Zusammesetzungen von cg250 und il-2 oder von cg250 und ifn-alpha zur krebsbehandlung des nierenzell karzinoms
SE0301936D0 (sv) * 2003-06-30 2003-06-30 Affibody Ab New polypeptide
SE0301987D0 (sv) * 2003-07-04 2003-07-04 Affibody Ab New polypeptide
DE602004018141D1 (de) * 2003-07-04 2009-01-15 Affibody Ab Polypeptide mit bindungsaffinität für her2
WO2005113584A1 (en) * 2004-04-29 2005-12-01 Board Of Regents, University Of Texas System Methods and compositions comprising protein l immunoglobulin binding domains for cell-specific targeting
US20080254507A1 (en) * 2004-11-30 2008-10-16 Kiim Pharm. Lab, Inc. Anti-Hiv Drug, Polypeptide Constituting the Same, Gene Encoding the Polypeptide and Method of Producing the Anti-Hiv Drug
ES2379096T3 (es) * 2005-05-20 2012-04-20 Glaxosmithkline Llc Nuevos procedimientos
GB0524788D0 (en) 2005-12-05 2006-01-11 Affibody Ab Polypeptides
US9598489B2 (en) 2012-10-05 2017-03-21 The Trustees Of The Univeristy Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
WO2014153204A1 (en) 2013-03-14 2014-09-25 Salk Institute For Biological Studies Oncolytic adenovirus compositions
EP2940128A1 (en) 2014-04-30 2015-11-04 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Adenovirus comprising an albumin-binding moiety
EP3072900A1 (en) * 2015-03-27 2016-09-28 Medizinische Hochschule Hannover Anti-tumour medicament based on adenovirus
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
KR20180112024A (ko) 2016-02-23 2018-10-11 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현
CN110062630A (zh) 2016-12-12 2019-07-26 萨克生物研究学院 肿瘤靶向合成腺病毒及其用途
CN110590939B (zh) * 2019-09-20 2024-02-02 广州暨南大学医药生物技术研究开发中心有限公司 一种利用基因工程获得重组人纤连蛋白的方法
WO2021087019A1 (en) * 2019-11-01 2021-05-06 University Of Houston System Oncolytic virotherapy with induced anti-tumor immunity
CN116334010B (zh) * 2023-05-30 2023-08-29 中义(北京)健康研究院 一种重组单纯疱疹病毒及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
SE9400088D0 (sv) * 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
ATE382694T1 (de) * 1995-11-28 2008-01-15 Genvec Inc Vektoren und methoden zum gentransfer in zellen
SK159999A3 (en) 1997-05-28 2000-06-12 Genvec Inc Alternatively targeted adenovirus
CA2321135A1 (en) * 1998-02-17 1999-08-19 Uab Research Foundation Modified adenovirus containing a fiber replacement protein
AU773202B2 (en) 1998-08-27 2004-05-20 Aventis Pharma S.A. Targeted adenovirus vectors for delivery of heterologous genes
EP1112372A1 (en) * 1998-09-11 2001-07-04 Genvec, Inc. Alternatively targeted adenovirus
WO2001002431A1 (en) * 1999-07-06 2001-01-11 Got-A-Gene Ab Recombinant adenovirus

Also Published As

Publication number Publication date
US20040132007A1 (en) 2004-07-08
PL360350A1 (en) 2004-09-06
EP1301613A2 (en) 2003-04-16
NO20030239D0 (no) 2003-01-17
AU2001270879B2 (en) 2007-09-20
NO20030239L (no) 2003-03-18
WO2002008263A2 (en) 2002-01-31
JP2004504062A (ja) 2004-02-12
AU7087901A (en) 2002-02-05
CA2413851A1 (en) 2002-01-31
US7456008B2 (en) 2008-11-25
NZ524251A (en) 2004-07-30
WO2002008263A3 (en) 2002-06-13
IL153879A0 (en) 2003-07-31
CN1443243A (zh) 2003-09-17
GB0017720D0 (en) 2000-09-06
CZ2003152A3 (cs) 2003-05-14
MXPA03000449A (es) 2004-12-13

Similar Documents

Publication Publication Date Title
BR0112624A (pt) Virús modificado, proteìna viral modificada, célula permissiva para um vìrus modificado, métodos para produzir um vìrus modificado em cultura de células, para regular a replicação de um vìrus modificado, para determinar a adequalibilidade de um polipeptìdeo não nativo para uso na preparação de um vetor viral e para ensair a solublidade de um polipeptìdeo não nativo ou de uma proteìna viral modificada, uso do vìrus modificado, e, composição farmacêutica
Canalis et al. Stimulation of DNA and collagen synthesis by autologous growth factor in cultured fetal rat calvaria
Belzacq et al. The adenine nucleotide translocator in apoptosis
Todaro et al. Growth factors produced by sarcoma virus-transformed cells
Broering et al. Mammalian reovirus nonstructural protein μNS forms large inclusions and colocalizes with reovirus microtubule-associated protein μ2 in transfected cells
Scherer et al. Studies on the propagation in vitro of poliomyelitis viruses: IV. Viral multiplication in a stable strain of human malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma of the cervix
Zaitsev et al. H1 and HMG17 extracted from calf thymus nuclei are efficient DNA carriers in gene transfer
Wang et al. Efficient therapeutic delivery by a novel cell-permeant peptide derived from KDM4A protein for antitumor and antifibrosis
Mukhopadhyay et al. Serum starvation induces anti-apoptotic cIAP1 to promote mitophagy through ubiquitination
Klingenberg et al. Inability of the acidic fibroblast growth factor mutant K132E to stimulate DNA synthesis after translocation into cells
Chen et al. Efficient prodrug activator gene therapy by retroviral replicating vectors prolongs survival in an immune-competent intracerebral glioma model
Tucker et al. Transient transfection of polarized epithelial monolayers with CFTR and reporter genes using efficacious lipids
Fansa et al. The N‐and C‐terminal ends of RPGR can bind to PDE 6δ
Moore et al. Regulation of intracellular calcium in chick embryo fibroblast: calcium uptake by the microsomal fraction
Meng et al. Efficient transfection of non‐proliferating human airway epithelial cells with a synthetic vector system
Yu et al. HIV-TAT-fused FHIT protein functions as a potential pro-apoptotic molecule in hepatocellular carcinoma cells
Knepper et al. The presence of transcription factors in fetal bovine sera
Grosjean et al. Multiple glycerol shocks increase the calcium phosphate transfection of non-synchronized CHO cells
Raisz et al. Effect of calcium on uptake of α-aminoisobutyric acid by parathyroid glands
Gluck The osteoclast as a unicellular proton-transporting epithelium
Babcock et al. Stable cell line of rat nephroma in tissue culture.
Yamane et al. In vitro transformation of cells of hamster brain by adenovirus type 12
King et al. Nonradioactive ligand binding assay for epidermal growth factor receptor
Petrie et al. Intracellular antibody against Clostridium perfringens enterotoxin fails to counteract toxin-induced damage
Raška Jr et al. Double-stranded DNA binding of adenovirus type 12 tumor antigen

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A E 7A ANUIDADE

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1963 DE 19.08.2008.